{"id":"NCT02721069","sponsor":"Neurelis, Inc.","briefTitle":"Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects","officialTitle":"A 12-Month Open-Label, Repeat-Dose Safety Study of NRL-1 in Epilepsy Subjects (DIAZ.001.05)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-04-11","primaryCompletion":"2020-06-17","completion":"2020-07-23","firstPosted":"2016-03-28","resultsPosted":"2022-01-31","lastUpdate":"2022-01-31"},"enrollment":175,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acute Repetitive Seizures","Breakthrough Seizures"],"interventions":[{"type":"DRUG","name":"NRL-1","otherNames":["Intranasal diazepam"]}],"arms":[{"label":"NRL-1","type":"EXPERIMENTAL"}],"summary":"This is a 12 month safety study to evaluate the safety of repeated doses of NRL-1","primaryOutcome":{"measure":"Number of Participants Who Received NRL-1 (Valtoco)","timeFrame":"12 months","effectByArm":[{"arm":"NRL-1 5mg","deltaMin":9,"sd":null},{"arm":"NRL-1 10mg","deltaMin":54,"sd":null},{"arm":"NRL-1 15 mg","deltaMin":46,"sd":null},{"arm":"NRL-1 20mg","deltaMin":54,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":5,"countries":["United States"]},"refs":{"pmids":["38175488","37455404","35816831","34418086","34033266","34022621"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":9},"commonTop":["Nasopharyngitis","Upper Respiratory Tract Infection","Pyrexia","Seizure","Influenza"]}}